Clinical Trials Logo
  1. Home
  2. Hepatitis C Virus Infection
  3. NCT02939989

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study — MAGELLAN-3  

Hepatitis C Virus Infection Clinical Trial

Official title:
An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies (MAGELLAN-3)

Clinical Trial Summary

The purpose of this study was to evaluate the efficacy and safety of co-administration of glecaprevir (ABT-493)/pibrentasvir (ABT 530) plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT) 1 - 6-infected participants (including non-cirrhotic, or cirrhotic with compensated cirrhosis participants) who had experienced virologic failure in an AbbVie parent clinical study.

Clinical Trial Description

This study enrolled HCV infected adults who had experienced virologic failure following treatment with glecaprevir/pibrentasvir or paritaprevir/ritonavir/ombitasvir + dasabuvir (DSV) (3D) or paritaprevir/ritonavir/ombitasvir (2D) regimens in one of the following AbbVie hepatitis C virus parent studies: - M13-594 (NCT02640157) - M13-596 (NCT02692703) - M14-172 (NCT02642432) - M14-242 (NCT02493855) - M14-868 (NCT02243293) - M15-410 (NCT02446717) - M15-592 (NCT03222583) - M16-126 (NCT02966795) - M16-135 (NCT03089944) ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02939989
Study type Interventional
Source AbbVie
Contact
Status Completed
Phase Phase 3
Start date November 21, 2016
Completion date July 30, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT02487030 - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection Phase 3
Active, not recruiting NCT05460130 - Implementing HCV Treatment for High-risk Populations in Austin, Texas N/A
Completed NCT02220998 - Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection Phase 3
Terminated NCT01052090 - Safety and Efficacy Study in Hepatitis C Patients With PHN121 Phase 1/Phase 2
Completed NCT02537379 - Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection N/A
Recruiting NCT04156945 - Interventions to Curb Hepatitis C Reinfections Among Men Who Have Sex With Men N/A
Terminated NCT02510300 - A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
Withdrawn NCT04309734 - Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects Phase 1/Phase 2
Active, not recruiting NCT04001608 - Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients Phase 3
Completed NCT04112303 - Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis Phase 3
Completed NCT02251717 - Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection Phase 2
Recruiting NCT05092074 - Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection
Recruiting NCT04005248 - Prevalence of HCV in HIV-negative MSM N/A
Completed NCT02249182 - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection Phase 2
Completed NCT01718145 - A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects Phase 3
Completed NCT01482611 - A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382 Phase 1
Completed NCT00255177 - Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients Phase 2
Terminated NCT02600351 - Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies Phase 3
Completed NCT04980157 - CARES-HCV: Promoting Screening Uptake Among Diverse Baby Boomers
Completed NCT02350569 - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting Phase 2